Mirum Phar­ma­ceu­ti­cals’ re­cent­ly pur­chased chron­ic he­pati­tis delta treat­ment has scored a Phase 3 win, adding mo­men­tum be­hind the com­pa­ny’s pipeline and com­mer­cial fu­ture.

More than...

The White House­'s Of­fice of Man­age­ment and Bud­get (OMB) is ask­ing for more in­for­ma­tion on the do­mes­tic pro­duc­tion of 86 es­sen­tial med­i­cines, such as the...

Adicet Bio re­port­edthat its off-the-shelf CAR-T ther­a­py im­proved symp­toms for lu­pus pa­tients in an ear­ly-stage study, and it plans to soon start a piv­otal...

Af­ter win­ning FDA ap­proval at the end of last year, two non­prof­its are now launch­ing their rare im­mune dis­ease gene ther­a­py Waskyra with a list...

The FDA has ap­proved the third treat­ment for a de­bil­i­tat­ing ge­net­ic dis­ease that turns mus­cle and con­nec­tive tis­sue to bone.

Mirum Phar­ma­ceu­ti­cals’ zil­ur­gis­ert­ib, which blocks...